title: [Incidence of tuberculostatic-resistant Mycobacterium tuberculosis. Clinical aspects and impact on therapy and clinical course].
abstract: BACKGROUND
  To know the incidence of Mycobacterium tuberculosis resistant to anti-tuberculin drugs in addition to the clinical features, treatment and evolution of the patients.
  
  
  METHODS
  This was a retrospective study of the clinical histories of patients with isolation of Mycobacterium tuberculosis with some type of resistance studied from January 1980 to April 1992.
  
  
  RESULTS
  During the period studied 470 patients were diagnosed with tuberculosis by cultures. In 30 of these cases (6.4%) Mycobacterium tuberculosis resistant to Isoniazide (8), Streptomycin (6), Isoniazide + Rifampicin (4), Isoniazide + Streptomycin (3), Isoniazide + Ethambutol (2), Isoniazide + Rifampicin + Streptomycin (2), Isoniazide + Rifampicin + Ethambutol (2), Rifampicin (1), Ethambutol (1), Isoniazide + Pyrazinamide (1) and Isoniazide + Rifampicin + Streptomycin + Ethambutol (1) were isolated. Clinical information was obtained on 23 patients, with the most frequent clinical pictures being those of respiratory infection (15). Five cases occurred in HIV+ patients. The resistance was considered as primary in 58.97% of the cases with modifications in empiric treatment being necessary in 6 cases. In 15 out of the 19 patients from whom the data of the follow up was obtained the evolution was good.
  
  
  CONCLUSIONS
  Resistance to Mycobacterium tuberculosis was 6.4%, with the high number of strains resistant to Rifampicin being of note. In 79% of the cases in which follow up data was obtained the resistance had no impact on treatment due to the good evolution of the patients in relation with the treatment used.
authors.affiliation: Servicio de Microbiología, Fundación Jiménez Díaz, Madrid.
authors.forename: J
authors.initials: J
authors.lastname: Esteban
authors.forename: M I
authors.initials: MI
authors.lastname: Gegúndez
authors.forename: P
authors.initials: P
authors.lastname: García-Corbeira
authors.forename: F
authors.initials: F
authors.lastname: Soriano
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015897:Comorbidity; D004352:Drug Resistance, Microbial; D005260:Female; D015658:HIV Infections / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents
vernacular_title: Incidencia de Mycobacterium tuberculosis resistente a tuberculostáticos. Aspectos clínicos e impacto sobre la terapia y evolución.